(Q44963388)

7 December 2017

title

Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation (English)

1 reference

7 December 2017

0 references

0 references

1 reference

Gaetano Ciancio

1

1 reference

7 December 2017

George W Burke

2

1 reference

7 December 2017

Adela Mattiazzi

3

1 reference

7 December 2017

Zvi Leibovici

4

1 reference

7 December 2017

Lorraine Dowdy

5

1 reference

7 December 2017

David Roth

6

1 reference

7 December 2017

Warren Kupin

7

1 reference

7 December 2017

Anne Rosen

8

1 reference

7 December 2017

Delvis Jorge

9

1 reference

7 December 2017

Robert E Cirocco

10

1 reference

7 December 2017

Joshua Miller

11

1 reference

7 December 2017

publication date

1 August 2004

1 reference

7 December 2017

published in

Clinical Transplantation

1 reference

7 December 2017

volume

18

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

402-406

1 reference

Infection in organ-transplant recipients

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

Cytomegalovirus drug resistance and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00180.X

10.1111/J.1399-0012.2004.00180.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference